Research programme: peptide hybrids - Amylin Pharmaceuticals

Drug Profile

Research programme: peptide hybrids - Amylin Pharmaceuticals

Alternative Names: AC 164209; Amylinomimetic/GRA peptide hybrid; GLP-1 receptor agonist/amylin analogue hybrid; GLP-1 receptor agonist/amylin mimetic hybrid; GLP-1 receptor agonist/amylinomimetic hybrid; GRA/amylinomimetic peptide hybrid; INTO

Latest Information Update: 12 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Peptides; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 07 Nov 2013 Discontinued - Preclinical for Diabetes mellitus in USA (SC)
  • 07 Nov 2013 Discontinued - Preclinical for Obesity in USA (SC)
  • 25 Dec 2012 Amylin Pharmaceuticals and Takeda terminate their agreement for this research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top